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Abstract
Background: The renin-angiotensin system (RAS) has been implied in the pathogenesis of various
diseases including acute and chronic pancreatitis. Angiotensin-converting enzyme (ACE) is the key
enzyme in activating the RAS. Deletion (D)-type polymorphism in the 16th intron of the ACE gene has
been associated with higher serum levels of the enzyme. Inhibition of ACE was found to ameliorate acute
pancreatitis in animal models suggesting that ACE plays a role in pathogenesis and progression of acute
pancreatitis. Objectives were to investigate the occurrence of the ACE insertion/deletion (I/D) polymor-
phism in acute pancreatitis patients and its association with the severity of the disease.
Material and Methods: Seventy-nine acute pancreatitis patients and 95 healthy controls were evalu-
ated. Acute pancreatitis cases were grouped as mild or severe according to the Atlanta criteria. Main
outcome measure: The presence of the ACE I/D polymorphism.
Results: ACE gene I and D allele frequency of patients (44% and 56%) were similar to controls (45% and
55%, respectively). There were no significant differences in severity of pancreatitis between patients with
the ACE-insertion or ACE-insertion/deletion versus ACE-deletion genotypes.
Conclusions: The ACE gene deletion polymorphism is neither a risk factor for development of acute
pancreatitis nor contributes to the severity of disease or development of complications.
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Introduction
Acute pancreatitis (AP) is a common acute inflammatory disease
of the pancreas after injury through multiple aetiologies.1
Pancreatic inflammation is initiated by pancreatic injury, most
commonly through activation of trypsinogen and other pancreatic
zymogens leading to autodigestion.2 A number of environmental
and genetic factors could be important in increasing susceptibility
to acute pancreatitis. Once AP is initiated, the majority of patients
have mild disease. However, about 20% progress to a severe course
with increased mortality and morbidity.3 The precise mechanisms
determining the severity of the immune response and various
complications in AP relative to the degree of injury are largely
unknown. The identification of genetic risk factors would help to
predict the risk and severity of the disease at an early stage.
Components of the renin-angiotensin system (RAS) contribute
to the pathogenesis of various inflammation-associated diseases.4
The RAS participates in the development of inflammation and
fibrosis in the heart, kidney, lung and liver through the regulation
of cell growth and inflammation, induction of oxidative stress
and worsening of fibrosis.5–7 The key enzyme in the RAS system
is an angiotensin-converting enzyme (ACE) that converts
angiotensin-I to the potent vasoconstrictor angiotensin-II.8,9
The RAS that is intrinsic to the pancreas plays a physiologic
role in the regulation of pancreatic endocrine and exocrine*These authors contributed equally to this work.
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functions.10–12 Moreover, pathological conditions including acute
pancreatitis and chronic hypoxia result in upregulation of the
pancreatic RAS components.13 Several studies have shown that
inhibition of RAS may ameliorate the severity of experimental
acute pancreatitis suggesting that variations in expression of ACE
could play a role in the development or progression of acute
pancreatitis.
The ACE gene insertion/deletion (I/D) polymorphism was dis-
covered and defined within the last decade.14 The deletion poly-
morphism of a 287-bp fragment of intron 16 of the ACE gene has
been shown to result in higher levels of circulating enzyme in a
dose-dependent manner.14,15 Although the ACE DD genotype has
been linked to several inflammatory diseases, the prevalence of
the ACE polymorphism in subjects with acute pancreatitis versus
controls and mild AP cases versus severe AP has not been
reported. Recently, we reported that the ACE I/D polymorphism
was not a risk factor in chronic pancreatitis.16 This brought the
hypothesis that the pancreas has its own local RAS and alternative
enzymes that bypass ACE.We tested this hypothesis by investigat-
ing the prevalence of the ACE polymorphism in patients with
acute pancreatitis compared with controls.
Materials and methods
Patients
The study was carried out with the approval of the institutional
review board of the University of Pittsburgh Medical Center.
Seventy-nine consecutive patients (41 males and 38 females,
mean age 51.50  19.71 years) admitted to the University of
Pittsburgh Medical Center with acute pancreatitis were recruited
through the pilot phase of the Severity of Acute Pancreatitis 1
(SAPS1) study. Written informed consent was obtained from
all subjects and the study protocol conforms to the ethical
guidelines of the Declaration of Helsinki. Ninety-five healthy
volunteers (40 male, 55 female, mean age 67.06  9.96 years)
recruited through the North America Pancreatitis 2 study were
used as the control group.
The diagnosis of AP was based on the presence of abdominal
pain and elevation of amylase and/or lipase serum levels at least
three times above the upper limit of normal. The time interval
between the onset of symptoms and admission to the hospital was
less than 4 h. Acute Physiology and Chronic Health Evaluation
(APACHE-II) score17 and Ranson criteria scores18 were calculated
for all patients. Patients were classified into two groups according
to APACHE-II and Ranson scores: mild AP cases who had peak
APACHE-II score <8 or 48-h Ranson score <3 or severe AP if
APACHE-II score was equal or greater than 8 and Ranson score
was 3 or more.19 The patients were only classified as severe AP
cases if both criteria indicated so.
Laboratory procedure
Genomic DNA was purified from peripheral blood cells using the
Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN,
USA).20 The blood samples from many of the AP subjects were
visibly abnormal, resistant to DNA separation with Puregene and
necessitated an alternative DNA extraction process. DNA was
purified using the QIA amp DNA blood mini kit (Qiagen,
Valencia, CA, USA) as described by Scherczinger et al.21 To deter-
mine the ACE genotype, a genomic DNA fragment on intron 16 of
theACE gene was amplified by PCR according to Rigat’s method.14
The amplifiedACEgene fragmentswithout insertion (Dallele) and
with insertion (I allele) of approximate 190 and 490 bp, respec-
tively, were detected on 1% agarose gel containing ethidium
bromide.To increase the specificity of DDgenotyping,PCR ampli-
fications were performed with an insertion-specific primer pair
(5 prime TGGGACCACAGCGCCCGCCACTAC 3 prime and 5
prime TCGCCAGCCCTCCCATGCCCATAA 3 prime), that only
the I allele produces a 335-bp amplicon. The 335-bp fragment was
identified on 1.5% agarose gel containing ethidium bromide. The
reaction yielded no products in the samples of DD genotype.22
Statistics analyses
Results are given as mean  SD or allele frequencies. Armitage’s
trend test, standard odds ratio analyses and the one- and two-way
analysis of variance (anova) were used to compare AP cases and
control subjects. 95% confidence interval and two-tailed P-values
were calculated. The study was powered to detect a relative risk
of three in AP cases (94.4%) (http://calculators.stat.ucla.edu/
powercalc).
Results
The characteristics of the 79 AP patients (51.50  19.71, male/
female 41/38) are summarized in Table 1. The mean age of the
healthy controls was significantly higher than the AP group (P <
0.001), whereas there was no difference in gender distribution
(P = 0.197). The aetiology of pancreatitis was diagnosed as biliary
in 23 patients, idiopathic in 19 patients and post-endoscopic
retrograde cholangiopancreatography procedure (ERCP) in 20
patients, alcohol in 8 patients and other causes in the remaining.
Median APACHE-II and Ranson disease severity scores were 5
(0–25) and 1 (0–8), respectively, in patients.
Sixteen patients were diagnosed as severe AP (mean age 59.25
17.15 years; vs. mild cases P = 0.078 and vs. control group P <
0.001). The mean APACHE score was 14.5 (3–25) and Ranson
score was 4 (1–8) in the severe AP group. Signs of remote organ
failure including shock, pulmonary insufficiency and renal failure
were present in all 16 subjects. Sixty-six patients (mean age 49.53
 19.96 years) were diagnosed as mild AP and had a median
APACHE-II score of 4 (0–14) (vs. severe AP P < 0.001) and
Ranson score of 1 (0–3) (vs. severe AP P < 0.001).
The frequency of ACE I/D genotypes are summarized in
Table 2. Allele frequency of the ACE deletion was 54% in AP
patients and 55% in healthy controls (P = 0.452). Frequency of the
ACE-DD genotype compared with the II or ID genotype was not
different between the AP group and controls (P = 0.41). Although
the ACE-DD genotype was slightly higher in severe cases there was
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no significant difference between mild AP, severe AP cases and
controls in genotype distribution (P = 0.766, Table 2).
When all patients were categorized according to their ACE
genotype, the median APACHE-II score was 5 (0–25), Ranson
score was 1 (0–8) and mean age 47.11  17.25 years in patients
with the ACE-DD genotype. Patients who carry the ACE-II or
ACE-ID genotype had anAPACHE-II of 5 (0–25), Ranson score of
1 (0–6) and mean age of 53.78  20.67 years. Although patients
with the ACE-DD genotype had slightly higher APACHE-II and
Ranson scores the difference was not significant (P = 0.393, P =
0.299 and P = 0.155, respectively). There was no differences
between patients with ACE-II, ID and DD genotypes in
APACHE-II and Ranson scores whereas mean age was lower in
patients with the ACE-DD genotype (P = 0.135, P = 0.414 and P =
0.007, respectively). There was no significant association between
systemic complications of pancreatitis and the ACE-DD genotype.
Discussion
In the past decade, the association between genetic functional
polymorphisms and inflammatory disease has drawn a great deal
of attention. The majority of pancreatic diseases are associated
with genetic polymorphisms.23 Specific variations in the genomic
DNA sequences of individuals strongly influence their suscepti-
bility to pancreatitis, the nature and severity of the inflammatory
process and the likelihood of complications.
Acute pancreatitis is a multifactorial inflammatory disease
caused by the activation of several proteolytic enzymes and pep-
tides.24 The RAS system has been shown to play an important
role in the regulation of pancreatic functions under pathological
and physiological conditions.12 RAS components may be the other
mediators involved in the pathogenesis of acute pancreatitis.
Angiotensin II, for example, stimulates the synthesis and secretion
of vascular permeability factors,25,26 adhesion molecules and
chemokines.27 It also induces migration and adhesion of mono-
cytes and leukocytes.28 Furthermore, tissue injury and acute
inflammations induce production of circulating angiotensinogens
and local angiotensins.29 Indeed, Greenstein et al.30 reported an
increased plasma RAS activity in patients with AP. In animal
models of AP and chronic pancreatitis with hypoxia, the compo-
nents of local pancreatic RAS were markedly elevated.11,31,32
Several studies demonstrated that inhibition of RAS attenuates
Table 1 The demographic and clinical characteristics of acute pancreatitis patients
Severe AP Mild AP Total P-value
Age 59.2.1  17.1 49.5  19.9 51.50  19.71 P < 0.001
Gender(male/female) 11/5 30/33 41/38 NS
Aetiology NS
Biliary 5 18 23
Alcohol 2 6 8
Post-ERCP 4 16 20
Hypertriglyceridemia 1 3 4
Drugs 1 2 3
Tumours – 2 2
Idiopathic 3 16 19
Severity
APACHE II 14.5 4 5 P < 0.001
(median, range) (3–25) (0–14) (0–25)
Ranson score 4 1 1 P < 0.001
(median, range) (1–8) (0–3) (0–8)
AP, acute pancreatitis; NS, non-significant; ERCP, endoscopic retrograde cholangiopancreatography procedure; APACHE, Acute Physiology and
Chronic Health Evaluation.
Table 2 Genotype distribution of ACE gene in severe and mild acute pancreatitis and healthy controls
Severe acute
pancreatitis (n = 16)
Mild acute pancreatitis
(n = 63)
Healthy controls
(n = 95)
P-value
I (Allele frequency) 45% 45% 44% NS
D (Allele frequency) 55% 55% 56% NS
ACE-II 4 (25%) 14 (22%) 18 (19%) NS
ACE-ID 6 (37.5%) 28 (45%) 50 (53%) NS
ACE-DD 6 (37.5%) 21 (33%) 27 (28%) NS
ACE, angiotensin-converting enzyme; NS, non-significant.
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pancreatic inflammation in experimental model of acute pancre-
atitis.33,34 These data indicate that changes in local RAS compo-
nents could have a potential role in acute pancreatitis.
Based on the above observations, we hypothesized that func-
tional polymorphisms in the ACE gene would alter the clinical
course of AP. However, the ACE gene I/D polymorphism was not
associated with susceptibility to AP or severity of AP. The ACE
gene I/D allele frequencies were similar to previously reported
frequencies in American studies35 suggesting that the sample was
representative of the larger population. On the other hand, it has
been noted that the pathological risk of ACE-DD genotypes varies
between populations with different genetic and environmental
backgrounds,36,37 so that the possibility of an important effect of
this polymorphism in a polygenic or complex context cannot be
excluded. The study may also have been underpowered as there
was a trend towards the ACE-DD genotype being more frequent
in severe AP patients. However, the effect would likely be small
and there was no association between systemic complications of
AP and ACE genotype.
Studies in animals demonstrate that components of the RAS
influence the severity of acute pancreatitis.32 Although an ACE
plays an important role in the RAS, the factors influencing acti-
vation of ACE and regulation of ACE activity within various
tissues may differ.38,39 Added to tissue-specific factors are the pos-
sible roles of the activated pancreatic digestive enzymes, especially
trypsin and chymotrypsin.40 Chymotrypsin can act in a way
similar to chymase to convert angiotensinogen to angiotensin I
and II.39 Likewise trypsin can act on components of the RAS in a
way similar to tryptase to catalyse the conversion of angiotensin II
into angiotensin III and IV. The balance of digestive enzyme acti-
vation and inhibition in the course of acute pancreatitis is prob-
ably complex, and not enough is known about local conditions to
model this process. However, digestive enzyme activation may
bypass ACE in regulating the RAS in the course of acute pancre-
atitis making the genotypic differences in ACE expression level or
activity irrelevant.
The pancreas is a relative newcomer to the list of tissues with
an intrinsic angiotensin-generating system. However, the present
study shows that there is no relation between pathogenesis and
progression of acute pancreatitis and the ACE I/D polymorphism.
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